Healthcare dealmakers gathering in San Francisco for the industry's premier annual conference this week say they expect a ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Xavier Becerra, who has led the Department of Health and Human Services, says federal agencies are outmatched in a world of ...

The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma ...

UK women report significant breast enlargement after Pfizer COVID-19 vaccine. Possible link to rare condition PASH, but requires further research.

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

Five years after the COVID-19 pandemic hit South Carolina and the U.S., it is still changing health care, from wastewater ...

Even if you enjoy average annual returns of just 8%, that can make you a lot richer over long periods. And you can certainly ...

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...